Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Analysts maintain Palantir at Underperform ahead of Q4 earnings on modest Govt revenue expectations

Published 01/31/2024, 12:47 PM
Updated 01/31/2024, 12:50 PM
© Reuters.  Analysts maintain Palantir (PLTR) at Underperform ahead of Q4 earnings on modest Govt revenue expectations

With Palantir (NYSE:PLTR) set to report Q4 earnings next week on February 5, analysts remain largely negative on the stock, even as analysts at Jefferies and RBC Capital Markets reiterated their ‘Underperform’ ratings on the stock and price targets of $13 and $5 respectively. Wall Street expects Palantir’s Q4 EPS to come in at $0.0696 and revenue of $615.65.

RBC Capital Markets analysts cite a muted quarterly government spend tracker (except for NHS) and mixed commercial checks. While estimated government contracted value implies modest growth, mainly on account of the NHS deal, since the deal started only on November 22 and since non-NHS QCV is down mid-teens, RBC is allowing for the possibility for government revenue growth to end up below consensus.

They also expect no change in the Commercial business since the AIP launch.

“Despite the new boot camp strategy, the number one challenge cited by customers is maintaining in-house skills and competency centers, ultimately, leading to an over-reliance on Palantir's professional services, which are viewed as expensive,” analysts at RBC Capital Markets wrote in a note to clients Tuesday.

“We would also highlight ongoing push-back on the lack of pricing transparency and competitive differentiation with AIP. One interesting data point was Palantir seems to be vying to compete in deals outside its core competency (e.g., offering to build custom apps for resource scheduling typically served by HCM software),” they added.

RBC analysts also point to the fact that shares are trading at a significant premium to peers.

Jefferies on the other hand notes that the current valuation screens attractive relative to high-growth peers when taking a long-term view. However, they prefer other names for AI exposure, especially as the stock price already “embeds expectations for upside from AIP.”

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Jefferies expects commercial revenue growth in Q4 to drive overall revenue upside.

“Consensus estimates for 4Q commercial rev stand at $271M (or 26% y/y growth). On a y/y growth basis, consensus estimates imply a 300bps acceleration on a 600bps easier comp. On a q/q growth basis, estimates imply 8.2% sequential growth which would be the largest increase in over 8 quarters,” analysts at Jefferies wrote in a client note on Wednesday.

“We believe that the setup is demanding given the lack of visibility into AIP contributions to the commercial business and a GTM motion that is still early and has yet to be proven out,” they added.

While they expect government revenue growth, their expectations are more tempered given limited visibility on when deals will land.

“We believe expectations are reasonable and note that given the lumpiness in government contracts and associated rev recognition, any given quarter could see upside,” said Jefferies analysts.

Palantir stock is trading down 1.85% at $16.43 on Wednesday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.